Do you manage patients with schizophrenia?
Learn how you can get involved to support a nearby study that is enrolling qualified patients with moderate-to-severe negative schizophrenia symptoms
About the Research Study
The CONVOKE study, sponsored by Click Therapeutics and Boehringer Ingelheim, is a phase 3 study evaluating the efficacy and safety of 2 investigational digital therapeutics as an adjunct to standard-of-care antipsychotic therapy in adult patients with negative experiential symptoms of schizophrenia. The study is enrolling approximately 432 participants across the United States.
This study will look at 2 mobile applications (apps), called investigational digital therapeutics, to see whether they can support people with moderate-to-severe negative experiential symptoms of schizophrenia. Participants will use the CONVOKE study app alongside their current medications for schizophrenia. Study participation lasts approximately 22 weeks, including 4 study site visits and 3 phone calls. Participants will need to use the mobile app every day for 16 weeks.
For more study information, please reference:
How You Can Get Involved
As a health care provider (HCP) who manages patients with schizophrenia, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the CONVOKE study.
You will be asked to consult with patients in a neutral manner about the study and assess their interest in participating at a nearby study site. Patients may be able to take part if they:
- Are at least 18 years of age
- Have a primary diagnosis of schizophrenia
- Have been on a stable dose of antipsychotic medication for at least 12 weeks before the study treatment period
- Own a smartphone compatible with Android 10 or greater, or iOS 14 or greater
The Effectus Patient Identification and Consultation Program
Effectus Patient Identification and Consultation Program Overview
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients to the study site and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the study, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session.
Compensation at fair market value will be available for HCPs who participate and meet program requirements.
Why This Study Is Important
People with schizophrenia can experience a diminished capacity for enjoyment and motivation. These diminished capacities are called experiential negative symptoms. Medications commonly used for treating schizophrenia do not improve experiential negative symptoms. It is hoped that the digital therapeutics used in this trial might improve experiential negative symptoms.
Sign a services
agreement.
Receive a package of
program materials and
complete a simple, 1-hour
virtual training session.
Utilize key screening
criteria to identify
potentially eligible
patients.
If the patient meets the criteria,
conduct a neutral consultation
about the availability of the
nearby study and gauge the
patient’s interest.
If the patient is interested in
participation, our team of dedicated
Patient Facilitators help ensure a
smooth patient transfer from your
office to the study site.
The patient is scheduled
and presents at the study
site for the screening
appointment.
The patient’s enrollment
status is determined and is
relayed back to the treating
HCP by Effectus.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.
The Effectus Patient Identification and Consultation Program
Contact Us
Montana Markell, Project Coordinator
Phone: 973-753-2430
Email: mmarkell@effectusctr.com